RO-101

N/A

Report date: 2025/01/26 17:03:45

Base Information

Drug NameRO-101
Drug Alias NameAnti-VEGF-A/Ang-2 bispecific protein (RevOpsis Therapeutics)RO-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAngiopoietin-2 inhibitorsVascular endothelial growth factor A inhibitors
TargetsAngiopoietin-2Vascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRevOpsis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCleveland Clinic Cole Eye InstituteSouthern Illinois University School Of MedicineUniversity of Nevada +[5] 
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A